Kalvista Pharmaceuticals Stock Forecast, Price & News

Kalvista Pharmaceuticals' stock was trading at $8.86 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, KALV stock has increased by 72.0% and is now trading at $15.24.
View which stocks have been most impacted by COVID-19.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kalvista Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Kalvista Pharmaceuticals.

Kalvista Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, December 1st 2020.
View our earnings forecast for Kalvista Pharmaceuticals.

Kalvista Pharmaceuticals Inc (NASDAQ:KALV) released its earnings results on Monday, September, 14th. The specialty pharmaceutical company reported ($0.61) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.60) by $0.01. Kalvista Pharmaceuticals had a negative net margin of 229.45% and a negative return on equity of 37.71%.
View Kalvista Pharmaceuticals' earnings history.

3 analysts have issued twelve-month target prices for Kalvista Pharmaceuticals' shares. Their forecasts range from $25.00 to $30.00. On average, they anticipate Kalvista Pharmaceuticals' stock price to reach $27.50 in the next twelve months. This suggests a possible upside of 80.4% from the stock's current price.
View analysts' price targets for Kalvista Pharmaceuticals.

Kalvista Pharmaceuticals saw a decline in short interest during the month of September. As of September 30th, there was short interest totaling 247,900 shares, a decline of 16.4% from the September 15th total of 296,600 shares. Based on an average trading volume of 64,600 shares, the short-interest ratio is presently 3.8 days. Currently, 2.1% of the company's stock are short sold.
View Kalvista Pharmaceuticals' Short Interest.

Some companies that are related to Kalvista Pharmaceuticals include Nabriva Therapeutics (NBRV), Keros Therapeutics (KROS), Generation Bio (GBIO), Retrophin (RTRX), Supernus Pharmaceuticals (SUPN), BioXcel Therapeutics (BTAI), Innoviva (INVA), Indivior (INVVY), Rhythm Pharmaceuticals (RYTM), Amphastar Pharmaceuticals (AMPH), Nkarta (NKTX), Intercept Pharmaceuticals (ICPT), ImmunoGen (IMGN), Athenex (ATNX) and Repare Therapeutics (RPTX).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Kalvista Pharmaceuticals investors own include Heron Therapeutics (HRTX), Sorrento Therapeutics (SRNE), Cara Therapeutics (CARA), SCYNEXIS (SCYX), TG Therapeutics (TGTX), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX), Catalyst Pharmaceuticals (CPRX), Corbus Pharmaceuticals (CRBP) and Pfizer (PFE).

Kalvista Pharmaceuticals trades on the NASDAQ under the ticker symbol "KALV."

Kalvista Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include NEXT Financial Group Inc (0.03%). Company insiders that own Kalvista Pharmaceuticals stock include Albert Cha, Andreas Maetzel, Benjamin L Palleiko, Christopher Yea, Daniel B Soland, Edward P Feener, Life Sciences Fund Iv (Gp) Sv, Svlsf Iv, Llc, Thomas Andrew Crockett and Venrock Healthcare Capital Par.
View institutional ownership trends for Kalvista Pharmaceuticals.

KALV stock was purchased by a variety of institutional investors in the last quarter, including NEXT Financial Group Inc. Company insiders that have bought Kalvista Pharmaceuticals stock in the last two years include Albert Cha, and Daniel B Soland.
View insider buying and selling activity for Kalvista Pharmaceuticals.

Shares of KALV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of KALV stock can currently be purchased for approximately $15.24.

Kalvista Pharmaceuticals has a market capitalization of $272.92 million and generates $12.69 million in revenue each year. The specialty pharmaceutical company earns $-29,120,000.00 in net income (profit) each year or ($1.64) on an earnings per share basis. Kalvista Pharmaceuticals employs 33 workers across the globe.

The official website for Kalvista Pharmaceuticals is www.kalvista.com.

Kalvista Pharmaceuticals' mailing address is 55 Cambridge Parkway Suite 901E, CAMBRIDGE MA, 02142. The specialty pharmaceutical company can be reached via phone at 857-999-0075 or via email at [email protected]